FDA Approves New HIV Treatment Option

The FDA has approved Trogarzo (ibalizumab-uiyk), a new antiretroviral medication for the treatment of heavily treatment-experienced adults with HIV and whose infections cannot be treated with other therapies.

The treatment is administered intravenously once every 14 days and is used in combination with other antiretroviral medications.
________________________________________________________________________________

RELATED CONTENT
Generics For HIV: Complex Barriers Hurt Uptake 
ART Cuts Mortality Risk in Children With HIV and Tuberculosis
________________________________________________________________________________

The safety and efficacy of Trogarzo was evaluated in a clinical trial of 40 patients who had sustained high levels of HIV-RNA despite antiretroviral treatment. Overall, a majority of patients experienced significant decreases in their HIV-RNA levels 1 week after treatment, and after 24 weeks, 43% of participants achieved HIV-RNA suppression.

The most common adverse effects were diarrhea, dizziness, nausea, and rash.

—Michael Potts

Reference:

FDA approves new HIV treatment for patients who have limited treatment options [press release]. March 6, 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599657.htm.